ALFA Filings
Every announcement, straight from the exchange
Every Medplus Health Services adverse business impact announcement on NSE and BSE, newest first, each with its own page.
Time
7 announcements with these filters
Optival Health, a MedPlus subsidiary, had drug licences suspended at five Karnataka stores for 1–7 days. Expected impact is about Rs 8.66 lakhs.
Medplus Health Services' subsidiary Optival Health faced temporary drug license suspensions for two stores by Mysore regulators. The estimated operational impact is ₹0.02 Crore.
The FDA suspended the drug license of a Medplus subsidiary's store in Prabhadevi, Maharashtra for 15 days. The financial impact is estimated at Rs 14.25 lakhs.
Medplus Health's subsidiary Optival Health faces drug license suspensions for 5-8 days across four stores in multiple states. The expected financial impact is ₹0.17 Crore.
Optival Health Solutions, a subsidiary, received a one-day drug license suspension from the Drugs Control Administration for a violation of the Drugs and Cosmetics Act.
Optival Health Solutions, a subsidiary of Medplus Health Services, received a 4-day drug license suspension for an Odisha store, impacting financials by ₹0.02 Crore.
Medplus Health Services subsidiary Optival Health faces a seven-day drug license suspension at a Karnataka store. The financial impact of this regulatory action is ₹0.12 Crore.